Dianthus Therapeutics, Inc. (DNTH)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Biotechnology (Startups)	6.24M	2.83M	6.42M	1.48M
Biotechnology (Startups) Growth	120.63%	-55.96%	334.76%	-
Total	6.24M	2.83M	6.42M	1.48M
Total Growth	120.63%	-55.96%	334.76%	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
United States	6.24M	2.83M	6.42M	1.48M
United States Growth	120.63%	-55.96%	334.76%	-
Total	6.24M	2.83M	6.42M	1.48M
Total Growth	120.63%	-55.96%	334.76%	-

Source: S&P Global Market Intelligence.